XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3

Note 12 - Segment Data (Tables)

6 Months Ended

Sep. 30, 2024

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended September 30,								Six Months Ended September 30,
		2024				2023				2024				2023
Revenues (a):
Sterilization and Disinfection Control (b)		$	22,205			$	17,080			$	45,162			$	33,007
Clinical Genomics			11,499				15,549				22,903				28,918
Biopharmaceutical Development			11,867				9,207				23,875				19,096
Calibration Solutions			12,262				11,329				24,063				22,789
Total revenues		$	57,833			$	53,165			$	116,003			$	103,810
Gross profit:
Sterilization and Disinfection Control (b)		$	15,172			$	12,476			$	30,730			$	24,067
Clinical Genomics			5,906				7,727				12,396				14,455
Biopharmaceutical Development			7,167				5,509				15,126				11,942
Calibration Solutions			7,210				6,407				14,452				12,838
Reportable segment gross profit			35,455				32,119				72,704				63,302
Corporate and other (c)			-				(10	)			-				(10	)
Gross profit		$	35,455			$	32,109			$	72,704			$	63,292
Reconciling items:
Operating expense			31,947				32,169				63,616				64,016
Operating income (loss)			3,508				(60	)			9,088				(724	)
Nonoperating expense, net			(304	)			1,265				1,371				1,538
Earnings (loss) before income taxes		$	3,812			$	(1,325	)		$	7,717			$	(2,262	)

Schedule of Depreciation and Amortization Expense [Table Text Block]

		September 30,				March 31,
		2024				2024
Sterilization and Disinfection Control		$	5,920			$	7,014
Clinical Genomics			11,459				11,813
Biopharmaceutical Development			6,001				6,304
Calibration Solutions			6,358				7,544
Total inventories		$	29,738			$	32,675

X

- Definition

Tabular display of the depreciation and amortization recorded during the periods for reportable segments.

+ References

No definition available.

+ Details

Name:	mlab_ScheduleOfDepreciationAndAmortizationExpenseTableTextBlock
Namespace Prefix:	mlab_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration